NasdaqGS:CGONBiotechs
CG Oncology (CGON): Assessing Valuation After H.C. Wainwright’s Buy Rating and Key Clinical Results
If you have been following CG Oncology (CGON), the new attention from H.C. Wainwright might turn your head. The firm’s recent reiteration of a Buy rating, along with upbeat comments on progress for Cretostimogene, their promising therapy for hard-to-treat bladder cancer, has sparked a conversation among investors. H.C. Wainwright highlighted encouraging study results and the potential for more important data by year’s end, which could change how the market views CG Oncology’s future...